Cas:1061682-67-4 4-(3,3-Difluoropyrrolidin-1-yl)piperidine manufacturer & supplier

We serve Chemical Name:4-(3,3-Difluoropyrrolidin-1-yl)piperidine CAS:1061682-67-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(3,3-Difluoropyrrolidin-1-yl)piperidine

Chemical Name:4-(3,3-Difluoropyrrolidin-1-yl)piperidine
CAS.NO:1061682-67-4
Synonyms:4-(3,3-difluoro-1-pyrrolidinyl)piperidine
Molecular Formula:C9H16F2N2
Molecular Weight:190.23400
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:15.27000
Exact Mass:190.12800
LogP:1.34610

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-(3,3-difluoro-1-pyrrolidinyl)piperidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(3,3-difluoro-1-pyrrolidinyl)piperidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(3,3-difluoro-1-pyrrolidinyl)piperidine Use and application,4-(3,3-difluoro-1-pyrrolidinyl)piperidine technical grade,usp/ep/jp grade.


Related News: Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined. 4-(3,3-Difluoropyrrolidin-1-yl)piperidine manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 4-(3,3-Difluoropyrrolidin-1-yl)piperidine supplier Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry. 4-(3,3-Difluoropyrrolidin-1-yl)piperidine vendor Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined. 4-(3,3-Difluoropyrrolidin-1-yl)piperidine factory Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures.